Home » Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma
Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma
The UK’s National Institute for Health and Care Excellence (NICE) says certain patients with mantle-cell lymphoma can be considered for treatment with Tecartus, a personalized therapy developed by Kite Pharma, a Gilead Sciences subsidiary.
NICE says the treatment can be considered for patients with relapsed or refractory mantle-cell lymphoma who previously received a Bruton’s tyrosine kinase inhibitor, such as ibrutinib, and it is recommending the therapy for use by the National Health Service.
Tecartus is a CAR-T therapy that uses a patient’s white blood cells as modified in a laboratory to attack cancer cells before being infused back into the patient.
Upcoming Events
-
21Mar
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr